News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Business Standard Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
An amended Schedule 13G filing for Eupraxia Pharmaceuticals (EPRX) reveals that Manchester Management Company, LLC, Manchester Management PR, LLC, Manchester Explorer, L.P., James E. Besser, and Morgan C. Frank each report beneficial ownership of common shares ranging from approximately 4.1% to 4.5% of the …
Eupraxia Pharmaceuticals Inc. announced positive results from an analysis of its RESOLVE study, showing significant symptom improvements in eosinophilic esophagitis (EoE) patients treated with EP-104GI. The analysis revealed a substantial decrease in moderate to severe odynophagia and dysphagia, with severe symptoms dropping to zero …
Eupraxia Pharmaceuticals announced positive symptom response data from its Phase 1b/2a RESOLVE trial for EP-104GI in Eosinophilic Esophagitis (EoE) patients. The analysis showed significant reductions in moderate to severe odynophagia (pain swallowing) and dysphagia (difficulty swallowing) lasting up to 52 weeks post-treatment, with no …
This article provides a detailed overview of Eupraxia Pharmaceuticals, Inc. (EPRX) stock on the Toronto Stock Exchange, including its current price, historical performance, key financial statistics, and analyst ratings. It highlights the company's focus on drug delivery technology for conditions like arthritis and chronic …
Eupraxia Pharmaceuticals Inc. reported Q2 2026 EPS of $(0.23), surpassing analyst estimates of $(0.25) despite a wider net loss of $14.5 million, primarily due to increased R&D spending for its lead EoE asset, EP-104GI. The company maintains strong liquidity with $133.6 million in cash …
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported a quarterly loss of $0.23 per share, surpassing analyst estimates by $0.02. Shares saw a modest increase of 0.6% to $6.70, and the company maintains strong financial liquidity. Analyst sentiment for EPRX is mixed but generally positive, with a "Moderate …
Sharemaestro market context Price below Trend Line 52 weeks +27.1%Eupraxia Pharmaceuticals reported a widened net loss of $27.1 million for the six months ended June 30, 2026, primarily due to increased research and development and general and administrative expenses. Despite the larger loss, the company significantly boosted its liquidity by raising $58.6 million …
This article provides an earnings forecast for Eupraxia Pharmaceuticals Inc (EPRX), highlighting analyst ratings, target prices, and historical/projected EPS and revenue growth. Nine analysts currently rate EPRX as a "Buy" with a target price of USD 16.444, suggesting a 146.91% upside. The article also …
Sharemaestro market context Price below Trend Line 52 weeks +27.1%This article provides current stock information for Eupraxia Pharmaceuticals Inc (EPRX), showing its stock price, market capitalization, and a brief overview of available financial data sections on the TradingKey platform. It indicates that more news regarding EPRX is expected soon. The content primarily serves …
Sharemaestro market context Price below Trend Line 52 weeks +27.1%Eupraxia Pharmaceuticals Inc. has filed a short form base shelf prospectus and accompanying Form F-10 to register up to US$300,000,000 in mixed securities, including common shares, preferred shares, debt securities, warrants, subscription receipts, and units. These securities may be offered over a 25-month period …
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $18.00, significantly higher than its current price of $6.40. Despite the positive analyst sentiment, the company remains unprofitable, reporting a quarterly loss of $0.23 …
Sharemaestro market context Price below Trend Line 52 weeks +27.1%Bloom Burton has reiterated its Buy rating for Eupraxia Pharmaceuticals (EPRX.US) and maintained its target price at $14. This indicates continued confidence in the company's prospects by the investment firm.
Search by ticker symbol or company name and select a result to open its chart.